@article{37f054459b4e46b8998a232eff08061d,
title = "Can radiation-recall predict long lasting response to immune checkpoint inhibitors?",
abstract = "RR secondary to ICI (nivolumab in all patients) were observed in the lung (n = 1) or skin (n = 3). All patients had a long-term response to ICI and are currently alive with no active disease (Median FU from ICI discontinuation: 30 months). RR could reflect a beneficial immune activation and constitute a predictive clinical biomarker of ICI long-term efficacy.",
keywords = "Anti CTLA4, Anti PD-L1, Anti-PD1, Radioimmunotherapy",
author = "Eric Deutsch and Benjamin Besse and {Le Pavec}, J{\'e}r{\^o}me and {Le P{\'e}choux}, C{\'e}cile and Angela Botticella and Samy Ammari and Caroline Even and Caroline Robert and Antonin Levy",
note = "Publisher Copyright: {\textcopyright} 2020 Elsevier B.V.",
year = "2021",
month = jan,
day = "1",
doi = "10.1016/j.radonc.2020.09.037",
language = "English",
volume = "154",
pages = "125--127",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
}